163 related articles for article (PubMed ID: 36581093)
1. TNF-α‒Mediated Keratinocyte Expression and Release of Matrix Metalloproteinase 9: Putative Mechanism of Pathogenesis in Stevens‒Johnson Syndrome/Toxic Epidermal Necrolysis.
Olsson-Brown A; Yip V; Ogiji ED; Jolly C; Ressel L; Sharma A; Bergfeld W; Liu X; Khirwadkar N; Bellon T; Dickinson A; Ahmed S; Langton A; Watson R; Pirmohamed M; Carr DF
J Invest Dermatol; 2023 Jun; 143(6):1023-1030.e7. PubMed ID: 36581093
[TBL] [Abstract][Full Text] [Related]
2. TNF-α induced extracellular release of keratinocyte high-mobility group box 1 in Stevens-Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesis.
Nwikue G; Olsson-Brown A; Aboheimed N; Yip V; Jolly C; Luchian A; Ressel L; Sharma A; Bergfeld W; Ahmed S; Dickinson A; Pirmohamed M; Carr DF
J Dermatol; 2023 Sep; 50(9):1129-1139. PubMed ID: 37269158
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Combination Therapy With Etanercept and Systemic Corticosteroids for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Observational Study.
Zhang J; Lu CW; Chen CB; Wang CW; Chen WT; Cheng B; Ji C; Chung WH
J Allergy Clin Immunol Pract; 2022 May; 10(5):1295-1304.e6. PubMed ID: 35131514
[TBL] [Abstract][Full Text] [Related]
4. The use of etanercept for treatment of toxic epidermal necrolysis when toxic shock syndrome is in the differential.
So N; Leavitt E; Aleshin M; Worswick S
Dermatol Ther; 2018 Sep; 31(5):e12684. PubMed ID: 30175438
[TBL] [Abstract][Full Text] [Related]
5. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions.
Wang CW; Yang LY; Chen CB; Ho HC; Hung SI; Yang CH; Chang CJ; Su SC; Hui RC; Chin SW; Huang LF; Lin YY; Chang WY; Fan WL; Yang CY; Ho JC; Chang YC; Lu CW; Chung WH;
J Clin Invest; 2018 Mar; 128(3):985-996. PubMed ID: 29400697
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of case-control studies of cytokines in blister fluid and skin tissue of patients with Stevens Johnson syndrome and toxic epidermal necrolysis.
Stewart TJ; Farrell J; Frew JW
Australas J Dermatol; 2024 Jun; ():. PubMed ID: 38831709
[TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine.
Chen CB; Wang CW; Chung WH
Methods Mol Biol; 2022; 2486():37-54. PubMed ID: 35437717
[TBL] [Abstract][Full Text] [Related]
8. Biologic TNF-α Inhibitors for Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis.
Cao J; Zhang X; Xing X; Fan J
Dermatol Ther (Heidelb); 2023 Jun; 13(6):1305-1327. PubMed ID: 37178320
[TBL] [Abstract][Full Text] [Related]
9. Exosomal microRNAs from PBMCs stimulated with culprit drugs enhanced keratinocyte cell death in Stevens-Johnson syndrome/toxic epidermal necrolysis.
Suthumchai N; Buranapraditkun S; Thantiworasit P; Rerknimitr P; Wongpiyabovorn J; Khanaraksombat S; Reantragoon R; Klaewsongkram J
J Eur Acad Dermatol Venereol; 2023 Jul; 37(7):1375-1384. PubMed ID: 36840393
[TBL] [Abstract][Full Text] [Related]
10. Possible involvement of gelatinase A (MMP2) and gelatinase B (MMP9) in toxic epidermal necrolysis or Stevens-Johnson syndrome.
Gaultier F; Ejeil AL; Igondjo-Tchen S; Dohan D; Dridi SM; Maman L; Wierzba CB; Stania D; Pellat B; Lafont A; Godeau G; Gogly B
Arch Dermatol Res; 2004 Oct; 296(5):220-5. PubMed ID: 15449075
[TBL] [Abstract][Full Text] [Related]
11. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Lerch M; Mainetti C; Terziroli Beretta-Piccoli B; Harr T
Clin Rev Allergy Immunol; 2018 Feb; 54(1):147-176. PubMed ID: 29188475
[TBL] [Abstract][Full Text] [Related]
12. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases.
Abe R
J Dermatol Sci; 2008 Dec; 52(3):151-9. PubMed ID: 18657400
[TBL] [Abstract][Full Text] [Related]
13. [Mechanisms of Severe Cutaneous Adverse Reactions and a New Treatment Strategy].
Saito Y; Nakamura R
Yakugaku Zasshi; 2019; 139(12):1557-1562. PubMed ID: 31787645
[TBL] [Abstract][Full Text] [Related]
14. Toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Orphanet J Rare Dis; 2010 Dec; 5():39. PubMed ID: 21162721
[TBL] [Abstract][Full Text] [Related]
15. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review.
Zhang S; Tang S; Li S; Pan Y; Ding Y
J Dermatolog Treat; 2020 Feb; 31(1):66-73. PubMed ID: 30702955
[No Abstract] [Full Text] [Related]
16. [Recent progress in research of pathogeneses of Stevens-Johnson syndrome and toxic epidermal necrolysis].
Gao TT; Long Q
Zhonghua Yan Ke Za Zhi; 2016 Sep; 52(9):708-13. PubMed ID: 27647252
[TBL] [Abstract][Full Text] [Related]
17. Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients.
Saito N; Yoshioka N; Abe R; Qiao H; Fujita Y; Hoshina D; Suto A; Kase S; Kitaichi N; Ozaki M; Shimizu H
J Allergy Clin Immunol; 2013 Feb; 131(2):434-41.e1-9. PubMed ID: 23111236
[TBL] [Abstract][Full Text] [Related]
18. [News in severe clinical adverse drug reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)].
Martínez-Cabriales SA; Gómez-Flores M; Ocampo-Candiani J
Gac Med Mex; 2015; 151(6):777-87. PubMed ID: 26581536
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.
Hasegawa A; Abe R
F1000Res; 2020; 9():. PubMed ID: 32595945
[TBL] [Abstract][Full Text] [Related]
20. Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Tian CC; Ai XC; Ma JC; Hu FQ; Liu XT; Luo YJ; Tan GZ; Zhang JM; Li XQ; Guo Q; Zeng FQ; Shi ZR; Wang L
Ann Allergy Asthma Immunol; 2022 Sep; 129(3):360-365.e1. PubMed ID: 35598882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
